Core Insights - By 2025, China's overseas licensing of innovative drugs is expected to exceed 150 deals, with a total value reaching $130 billion, compared to $50 billion in 2024, indicating significant international recognition of China's pharmaceutical and medical device innovations [1] Group 1: Market Expansion and Challenges - Chinese pharmaceutical companies are shifting their export focus from raw materials and intermediates to innovative drugs, high-end formulations, and high-performance medical devices [2] - In the first eleven months of last year, China's pharmaceutical export value reached $100.895 billion, showing steady growth, but companies face increasing risks and challenges due to rising unilateralism and protectionism [2] - The Chinese government is encouraging regions to explore building trading platforms aimed at Southeast Asia, Central Asia, and other countries to enhance international promotion and allow more nations to benefit from China's pharmaceutical industry [2] Group 2: Cross-Border Initiatives - The China-ASEAN cross-border pharmaceutical procurement platform has successfully facilitated multiple cross-border transactions, including significant orders for domestic medical devices [3] - The China-Central Asia "Central Pharmacy" initiative has attracted innovative pharmaceutical and medical device companies to showcase over 2,200 medical devices, addressing the rigid demands of Central Asian countries [3] Group 3: Pricing Mechanisms and Support - The first overseas price registration certificate for a domestic drug treating infant vascular tumors has been issued, providing a crucial basis for companies to establish reasonable pricing in international markets [4] - The National Medical Insurance Administration is developing an international pharmaceutical pricing system that allows companies to set prices based on global market conditions rather than solely on domestic insurance payment prices [5] - A new pricing mechanism for newly launched drugs will be implemented to ensure that high-investment, high-risk innovative drugs have stable prices during their initial market entry, enhancing accessibility for quality products [5]

Core Viewpoint - The National Medical Insurance Administration (NMIA) is actively promoting the "going global" strategy for Chinese medical devices and pharmaceuticals, focusing on building a supportive ecosystem through the collection and pricing platform for medical supplies [1][11]. Group 1: Event Overview - The NMIA held a seminar on January 17, 2026, in Beijing, attended by over 400 representatives from various sectors, including government, international organizations, financial institutions, and media [1]. - The discussion centered on enhancing the functionality of the medical supplies collection and pricing platform to support the international expansion of Chinese medical products [1]. Group 2: Policy and Financial Support - Representatives from relevant ministries introduced policies to support Chinese medical devices and pharmaceuticals, while financial institutions presented comprehensive financial service plans for these companies [1][5]. - The NMIA aims to leverage regional advantages of collection platforms to innovate international procurement models and enhance the internationalization of China's pharmaceutical industry [5]. Group 3: Market Expansion and Infrastructure - The NMIA is focusing on the differentiated development of collection platforms in regions like Guangxi, Xinjiang, Tianjin, and Ningbo, targeting Southeast Asia, Central Asia, and other Belt and Road countries [5]. - The establishment of a global pricing system for Chinese pharmaceuticals is a priority, with the goal of making China a leading source for innovative drugs globally [5][11]. Group 4: Ecosystem Development - The event aims to create a tightly integrated ecosystem combining government, industry, finance, and services to empower the internationalization of Chinese medical devices [11]. - The initiative seeks to share the achievements of China's pharmaceutical innovation with the world and contribute to global health [11].